SCYNEXIS News

SCYNEXIS Eulerpool News

SCYNEXIS Stock News

SCYNEXIS is being monitored by journalists and investors worldwide. We gather the latest SCYNEXIS news here.

• December 22·

  Yahoo
  SCYNEXIS Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement
• December 22·

  Benzinga
  SCYNEXIS Receives Nasdaq Extension To Regain Bid Price Compliance By June 15, 2026
• November 25·

  Benzinga
  12 Health Care Stocks Moving In Tuesday's Pre-Market Session
• November 19·

  Yahoo
  SCYNEXIS Completes Transfer of BREXAFEMME® New Drug Application to GSK
• November 19·

  Benzinga
  SCYNEXIS Completes Transfer Of BREXAFEMME New Drug Application To GSK
• November 10·

  Yahoo
  Here's Why We're A Bit Worried About SCYNEXIS' (NASDAQ:SCYX) Cash Burn Situation
• October 15·

  Benzinga
  SCYNEXIS To Receive $22M From GlaxoSmithKline To Resolve Dispute Over Restarting The Phase 3 Mario Study For Invasive Candidiasis.
• September 30·

  Benzinga
  SCYNEXIS Reports Results From Phase 1 Study Of SCY-247, Second-Gen Triterpenoid Antifungal Under Development For Treatment And Prevention Of Invasive Fungal Infections
• May 29·

  Yahoo
  SCYNEXIS, Inc. (SCYX) Resumes Phase III Dosing for Brexafemme After 19-Month FDA Hold
• April 8·

  Yahoo
  SCYNEXIS to Present Preclinical Data on Second Generation IV/Oral Fungerp SCY-247 at the European Society of Clinical Microbiology and Infectious Diseases (ESCMID)
• March 14·

  Yahoo
  SCYNEXIS Full Year 2024 Earnings: Misses Expectations
• March 12·

  Yahoo
  SCYNEXIS Reports Full Year 2024 Financial Results and Provides Corporate Update
• November 8·

  Yahoo
  SCYNEXIS Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
• November 6·

  Yahoo
  Scynexis: Q3 Earnings Snapshot
• November 6·

  Yahoo
  SCYNEXIS Reports Third Quarter 2024 Financial Results and Provides Corporate Update
• October 13·

  Seeking Alpha
  Earnings week ahead: BAC, GS, JNJ, TSM, UNH, ABT, UAL, NFLX, PG, AXP and more
• October 10·

  Yahoo
  SCYNEXIS to Participate in the 2024 Maxim Healthcare Virtual Summit
• October 7·

  GuruFocus
  Federated Hermes, Inc. Expands Stake in SCYNEXIS Inc
• October 3·

  Yahoo
  SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at IDWeek 2024
• August 27·

  Yahoo
  SCYNEXIS to Participate in H. C. Wainwright 26th Annual Global Investment Conference

SCYNEXIS Stock Press Releases

SCYNEXIS regularly publishes news on the company's website that are relevant for investors.

• December 1•

  SCYNEXIS
  SCYNEXIS Announces FDA Approval of Second Indication for BREXAFEMME® (ibrexafungerp tablets) for Reduction in Incidence of Recurrent Vulvovaginal Candidiasis
• November 30•

  SCYNEXIS
  SCYNEXIS Announces $3 Million National Institutes of Health Grant Has Been Awarded to Case Western Reserve University Researchers to Study Second Generation Fungerp (SCY-247) to Fight Drug-Resistant Fungi
• November 17•

  SCYNEXIS
  SCYNEXIS Applauds the Biomedical Advanced Research and Development Authority (BARDA) for Its New Priority Focus on Investment in Development of Antifungal Treatments to Fight Infections Caused by Drug-Resistant Fungal Threats
• November 9•

  SCYNEXIS
  SCYNEXIS Reports Third Quarter 2022 Financial Results and Provides Corporate Update
• November 7•

  SCYNEXIS
  SCYNEXIS Announces Publication of Review Article Highlighting Ibrexafungerp as a Potential Novel Treatment for Invasive Mold Infections in the Journal of Fungi
• November 3•

  SCYNEXIS
  Pooled Data from the Pivotal Phase 3 VANISH Program Published in the Journal of Women’s Health Demonstrate Significant Efficacy of Ibrexafungerp Over Placebo for Treatment of Vaginal Yeast Infection
• November 1•

  SCYNEXIS
  SCYNEXIS to Report Third Quarter 2022 Financial Results and Provide a Corporate Update on November 9
• October 25•

  SCYNEXIS
  Biopharma Veteran Ivor Macleod Joins SCYNEXIS as Chief Financial Officer
• October 24•

  SCYNEXIS
  SCYNEXIS Presents Positive Interim Data of Oral Ibrexafungerp for Severe Fungal Infections from Ongoing Phase 3 FURI Study During IDWeek 2022
• October 20•

  SCYNEXIS
  SCYNEXIS Provides Corporate, Commercial and R&D Strategy Updates to Expand Market Potential for Its First-in-Class Antifungal
• October 11•

  SCYNEXIS
  SCYNEXIS to Present Positive Interim Data from the Phase 3 FURI Study of Oral Ibrexafungerp at IDWeek 2022
• September 9•

  SCYNEXIS
  SCYNEXIS to Participate in Upcoming September Investor Conferences
• September 8•

  SCYNEXIS
  SCYNEXIS Presents Positive Interim Data of Ibrexafungerp for Refractory Candida Infections from Ongoing Phase 3 FURI Study During the Mycoses Study Group Education and Research Consortium (MSGERC) Biennial Meeting
• September 1•

  SCYNEXIS
  SCYNEXIS to Present Posters Highlighting Ibrexafungerp Data at Four Upcoming Scientific Meetings in September 2022
• August 15•

  SCYNEXIS
  SCYNEXIS Reports Second Quarter 2022 Financial Results and Provides Corporate Update
• August 9•

  SCYNEXIS
  SCYNEXIS to Report Second Quarter 2022 Financial results and Provide a Corporate Update on August 15
• August 4•

  SCYNEXIS
  SCYNEXIS Presents Positive Data from Its Pivotal Phase 3 CANDLE Study of Oral Ibrexafungerp for Prevention of Recurrent Vaginal Yeast Infections During the 2022 IDSOG Annual Meeting
• August 1•

  SCYNEXIS
  SCYNEXIS Announces U.S. Food and Drug Administration Acceptance and Priority Review of the Supplemental New Drug Application for BREXAFEMME® (ibrexafungerp tablets) for Prevention of Recurrent Vaginal Yeast Infections
• July 19•

  SCYNEXIS
  SCYNEXIS Presents Positive Data from Phase 3 CANDLE Nested Sub-Study Investigating Ibrexafungerp in Women with Recurrent Yeast Infections Who Failed Fluconazole During the ISSVD XXVI World Congress and International Vulvovaginal Disease Update
• July 14•

  SCYNEXIS
  SCYNEXIS to Present Data from the CANDLE Nested Sub-Study of Ibrexafungerp During the International Society for the Study of Vulvovaginal Disease (ISSVD) XXVI World Congress and International Vulvovaginal Disease Update
• June 23•

  SCYNEXIS
  SCYNEXIS Announces Initiation of New Phase 3b Study (VANQUISH) to Evaluate Oral Ibrexafungerp as a Treatment for Complicated Vulvovaginal Candidiasis (VVC) in Patients Who Failed to Respond to Treatment with Fluconazole
• June 8•

  SCYNEXIS
  SCYNEXIS Announces Submission of Supplemental New Drug Application of BREXAFEMME® (ibrexafungerp tablets) to the U.S. Food and Drug Administration for an Expanded Indication for the Prevention of Recurrent Vaginal Yeast Infections
• June 3•

  SCYNEXIS
  SCYNEXIS Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
• May 20•

  SCYNEXIS
  SCYNEXIS to Present at Upcoming H.C. Wainwright Global Investment Conference
• May 12•

  SCYNEXIS
  SCYNEXIS Reports First Quarter 2022 Financial Results and Provides Corporate Update
• May 10•

  SCYNEXIS
  SCYNEXIS Presents New Interim Positive Data of Ibrexafungerp for Refractory Vulvovaginal Candidiasis from Ongoing Phase 3 FURI Study at the American College of Obstetricians and Gynecologists (ACOG) Annual Clinical & Scientific Meeting
• May 5•

  SCYNEXIS
  SCYNEXIS to Report First Quarter 2022 Financial Results and Provide a Corporate Update on May 12
• May 4•

  SCYNEXIS
  SCYNEXIS to Present New Data of Ibrexafungerp for Refractory Vulvovaginal Candidiasis from Ongoing Phase 3 FURI Study at the American College of Obstetricians and Gynecologists (ACOG) Annual Clinical & Scientific Meeting
• April 27•

  SCYNEXIS
  SCYNEXIS Presents Data Analyses Showing Ibrexafungerp’s Potential to Fight Invasive Candidiasis and Candidemia, Including Infections Caused by Candida Auris, During the 32nd Annual European Congress of Clinical Microbiology & Infectious Diseases
• April 26•

  SCYNEXIS
  SCYNEXIS Announces Closing of $45 Million Public Offering of Common Stock, Pre-Funded Warrants and Warrants